“…This was known to be chronic in 3 patients (1 with coronary artery disease, 1 with chemotherapy induced cardiomyopathy and 1 with dilated cardiomyopathy of unknown aetiology), whilst pre-morbid cardiac function was unknown in the other 2 patients. No patient had severe LVSD (LVEF ≤35%). …”
Enlace del recurso
Enlace del recurso

“…Among the 4 ARDS cases, two had preceding RS virus infection, and the other 2 developed ARDS during marrow recovery with G-CSF use. …”
Enlace del recurso
Enlace del recurso

“…Here, 3 patients were treated with Inj amphotericin B, while the other 2 patients were started on voriconazole with rifampicin sparing regimen for TB. …”
Enlace del recurso
Enlace del recurso

“…CI: 0.88–2.16, P = 0.17; the other 2 RCTs reported significantly higher DFS and OS rates in the PB group compared with the PF group, with the combined risk ratio for DFS in the PB group RR = 0.22 (95% CI:0.06–0.82, P = 0.015); the combined risk ratio for DFS in the PF group RR = 0.15 (95% CI. 0.04–0.61, P = 0.008); OS rate: PB vs PF = 0.046 vs 0.003; secondly, 2 RCTs showed that for patients with BRCA-mutated TNBC, the pCR rate in the PB and PF groups was 18% vs 26%, 95% CI: 2.4–4.2 vs 4.1–5.1; meanwhile, the median subject in the PB group The median PFS was 3.1 months (95% CI: 2.4–4.2) in the PB group and 4.4 months (95% CI: 4.1–5.1) in the PC group; finally, the results of the clinical adverse effects analysis showed that platinum-containing chemotherapy regimens significantly increased the incidence of adverse effects such as thrombocytopenia and diarrhea compared with non-platinum regimens, while the incidence of adverse effects such as vomiting, nausea, and neutropenia was reduced. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Adolescent mothers from 2 intervention subcounties received interactive text messaging only (limited package), whereas those from the other 2 subcounties received text messaging and weekly support groups, moderated by a community health extension worker and a counselor (full package); the control cluster only received the end-line evaluation (posttest-only control). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Analyses of annualized bleeding rates demonstrate comparable clinical outcomes of rVIII-SingleChain to the other 2 long-acting products assessed. In patients aged ≥ 12 years, rVIII-SingleChain prophylaxis may result in an 11.0% and 13.7% lower mean factor consumption than rFVIIIFc and PEG-rFVIII, respectively, representing a potential cost-saving opportunity of 34% in both cases—at the current wholesale acquisition cost of the corresponding products. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Severe maternal morbidity was higher for Black (2.9%; odds ratio, 1.44; 95% confidence interval, 1.24–1.67), Asian Pacific Islander (2.9%; odds ratio, 1.45; 95% confidence interval, 1.15–1.82), and other (2.8%; odds ratio, 1.36; 95% confidence interval, 1.21–1.54) compared with White race (2.1%) (P<.001). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Individuals in the high-acuity+low–self-harm profile completed treatment at a significantly lower rate relative to the other 2 high-acuity profiles (ꭓ(2)(3)=13.4, P=.004). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Homozygous T-to-C mutations in two alleles of FKS1gene was detected in 2 cases, and a heterozygous mutation was detected in the other 2 cases, which resulted in a deduced serine-to-proline amino acid change at position 654 (S654P). …”
Enlace del recurso
Enlace del recurso

“…In terms of ethnicity, TNBC vs. non-TNBC patients had the following racial backgrounds: black, 58.97% vs. 39.27%; white, 35.90% vs. 57.76%; Chinese, 2.56% vs. 0.99%; others, 2.57% vs. 1.98% respectively (P = 0.004, OR = 2.755). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Cox regression analysis found no difference in OS between vinflunine and other 2L treatments (P = 0.69). Conclusions: This study provides a contemporary multicenter assessment of real-world treatment patterns and outcomes among palliatively treated patients with UC in Germany. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Of the 3 (14%) PA patients with an abnormal POD1-CST, 1 was dischargedwith GR and began tapering after 2 weeks; the other 2 did not require GR and did not developAI. …”
Enlace del recurso
Enlace del recurso

“…The cisplatin group had significantly higher incidences of acute grade 3 or 4 neutropenia (69 events [60.8%] vs 19 [17.8%] for fluorouracil and 37 [34.6%] carboplatin; P < .001), thrombocytopenia (14 events [13.1%] vs 4 [3.7%] for fluorouracil and 5 [4.7%] for carboplatin; P = .01), anemia (50 events above grade 2 [46.7%] vs 25 [23.4%] for fluorouracil and 37 [34.6%] for carboplatin; P = .35), fatigue (11 events [10.3%] vs 2 [1.9%] for fluorouracil and 1 [0.9%] carboplatin; P = .007), and vomiting (17 events above grade 2 [15.9%] vs 3 [2.8%] for fluorouracil and 5 [4.7%] for carboplatin; P < .001) than the other 2 groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, paclitaxel plus fluorouracil did not show OS superiority over paclitaxel plus cisplatin or paclitaxel plus carboplatin regimens in definitive chemoradiation in patients with locally advanced ESCC. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SAR (ST2198) from patient 1 was S to all agents tested, as were the other 2 strains (ST2250 and ST1223), except for oxacillin. …”
Enlace del recurso
Enlace del recurso

“…RESULTS: 198 PCD patients (178 multiple myeloma, 15 amyloid, 3 SMM/MGUS, other 2 PCD), median age 63 (range 35-84), had serologic assessment after one vaccine dose against SARS-CoV-2. 69% (138) were on chemo-immunotherapy treatment (CIT) within 4 weeks of first dose. …”
Enlace del recurso
Enlace del recurso

“…The overall approval rate was higher for PCPs (49.8%, n=525/1,054) versus specialists (41.7%, n=206/494; OR=1.39, 95% CI=1.08-1.78, P=0.011) and for the category for guideline adherence interventions (44.0% for PCPs vs. 35.9% for specialists; OR=1.40, 95% CI=1.01-1.95, P=0.044), but not for the other 2 intervention categories. CONCLUSIONS: Prescriber approval rates for pharmacist recommendations for drug therapy changes for MTMP beneficiaries were approximately 47% overall and higher for recommendations that involved cost savings compared with recommendations for safety concerns or guideline adherence. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Two different representative samples of children aged 6–29 months and their mothers were surveyed in each arm, one before the intervention in 2014 (control: n = 1,301, intervention: n = 1,357), the other 2 years afterwards in 2016 (control: n = 996, intervention: n = 1,035). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Often in a series of twelve or more bouillon flasks which were prepared alike and inoculated with the same culture, some would cover the surface in eight days to two weeks, others would take four to six weeks, still others two to three months. It was thought in the beginning of the work that this variation might depend on the amount of oxygen within the flask or on the change in reaction in the bouillon, but further tests proved that neither of these influenced the rate of growth in any way. …”
Enlace del recurso
Enlace del recurso

“…CMV VL was undetectable subsequently; other 2 withdrew from study. One (2.1%) LET-treated patient developed breakthrough CMV viremia with a UL56 C325W mutation. …”
Enlace del recurso
Enlace del recurso

“…Early pilot studies by us to discover blood biomarkers for mood state were promising [1], and validated by others [2]. Recent work by us has identified blood gene expression biomarkers that track suicidality, a tragic behavioral outcome of mood disorders, using powerful longitudinal within-subject designs, validated them in suicide completers, and tested them in independent cohorts for ability to assess state (suicidal ideation), and ability to predict trait (future hospitalizations for suicidality) [3–6]. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso